EUVIMEDEUVIMED entdecken
Crossref

A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health Technologies

Paul Tappenden iD, Orla Hardiman iD, Sun-Hong Kwon iD, Mon Mon-Yee iD, Miriam Galvin iD, Christopher McDermott iD, ALS-CarE Study Group

PharmacoEconomics · 2024

DOI: 10.1007/s40273-024-01395-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PharmacoEconomics, 2024. Verfasst von Paul Tappenden und 6 weiteren Autor:innen. Beteiligte Einrichtung: SCHARR, University of Sheffield, Sheffield, UK. p.tappenden@sheffield.ac.uk. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Cost-Benefit Analysis, Quality-Adjusted Life Years, Models, Economic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: NIHR Sheffield BRC and an NIHR Research Professorship, EU Joint Programme – Neurodegenerative Disease Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a devastating disease which leads to loss of muscle function and paralysis. Historically, clinical drug development has been unsuccessful, but promising disease-modifying therapies (DMTs) may be on the horizon. OBJECTIVES: The aims of this study were to estimate survival, quality-adjusted life-years (QALYs) and costs under current care, and to explore the conditions under which new therapies might be considered cost effective. METHODS: We developed a health economic model to evaluate the cost effectiveness of future ALS treatments from a UK National Health Service and Personal Social Services perspective over a lifetime horizon using data from the ALS-CarE study. Costs were valued at 2021/22 prices. Two hypothetical interventions were evaluated: a DMT which delays progression and mortality, and a symptomatic therapy which improves utility only. Sensitivity analysis was conducted to identify key drivers of cost effectiveness. RESULTS: Starting from King's stage 2, patients receiving current care accrue an estimated 2.27 life-years, 0.75 QALYs and lifetime costs of £68,047. Assuming a 50% reduction in progression rates and a UK-converted estimate of the price of edaravone, the incremental cost-effectiveness ratio for a new DMT versus current care is likely to exceed £735,000 per QALY gained. Symptomatic therapies may be more likely to achieve acceptable levels of cost effectiveness. CONCLUSIONS: Regardless of efficacy, DMTs may struggle to demonstrate cost effectiveness, even at a low price. The cost effectiveness of DMTs is likely to be strongly influenced by drug price, the magnitude and durability of relative treatment effects, treatment starting/stopping rules and any additional utility benefits over current care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisCost-Benefit AnalysisQuality-Adjusted Life YearsModels, EconomicHumansUnited KingdomDisease ProgressionBiomedical TechnologyTechnology Assessment, Biomedical

Autor:innen und Institutionen

  • SCHARR, University of Sheffield, Sheffield, UK. p.tappenden@sheffield.ac.uk.
  • Academic Unit of Neurology, Trinity College Dublin, Dublin, Ireland.
  • SCHARR, University of Sheffield, Sheffield, UK.
  • Division of Neuroscience, University of Sheffield, Sheffield, UK.

ORCID-Profile: Paul Tappenden, Orla Hardiman, Sun-Hong Kwon, Mon Mon-Yee, Miriam Galvin, Christopher McDermott

Förderung

  • NIHR Sheffield BRC and an NIHR Research Professorship
  • EU Joint Programme – Neurodegenerative Disease Research

Zitieren

APA

Tappenden, P., Hardiman, O., Kwon, S. H., Mon-Yee, M., Galvin, M., McDermott, C., & ALS-CarE Study Group (2024). A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health Technologies. PharmacoEconomics. https://doi.org/10.1007/s40273-024-01395-7

Vancouver

Tappenden P, Hardiman O, Kwon SH, Mon-Yee M, Galvin M, McDermott C, et al. A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health Technologies. PharmacoEconomics. 2024. doi:10.1007/s40273-024-01395-7

BibTeX
@article{Tappenden2024,
  author = {Tappenden, Paul and Hardiman, Orla and Kwon, Sun-Hong and Mon-Yee, Mon and Galvin, Miriam and McDermott, Christopher and ALS-CarE Study Group, ALS-CarE Study Group},
  title = {A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health Technologies},
  journal = {PharmacoEconomics},
  year = {2024},
  doi = {10.1007/s40273-024-01395-7}
}
Kostenlos starten →